News

This designation is for treating patients diagnosed with HER2-positive metastatic breast cancer (MBC) that has progressed during or after at least two HER2-targeting treatment regimens for locally advanced

The study is expected to commence in the second half of 2018. The upcoming clinical phase I study with ATOR-1015 is a first-in-human dose escalation study in patients

Eli Lilly has developed Solanezumab, which is a monoclonal antibody-based treatment for Alzheimer’s disease. Researchers have projected that Alzheimer’s disease is caused by the development of a sticky

CINRYZE is an injectable prescription medicine that is used to help prevent swelling and/or painful attacks in teenagers and adults with Hereditary Angioedema (HAE), a rare genetic disease.

The aims of this grant are closely aligned with the current government national priorities to make the UK a global hub for manufacturing advanced therapies, which will benefit

The randomized, double-blind REFLECTIONS B3281006 clinical trial assessed the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 in comparison to rituximab. It demonstrated equivalence of the biosimilar candidate in

FlexFactory, which is a biomanufacturing platform based on single-use technologies, will be deployed at Clover’s facility in Changxing of Zhejiang. The facility is being built for the production of biological

Enochian is developing an innovative proprietary technology in the field of HIV/AIDS. DanDrit believes that through the acquisition, Enochian's technology will enhance DanDrit's research and development efforts and

The decision follows a positive recommendation for Orphan Designation from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). In Europe, an Orphan Designation is granted